NCT02632708 - Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | Biotech Hunter

Enrollment

153

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 13, 2018

Study Completion Date

July 24, 2026

Conditions

Newly Diagnosed Acute Myeloid Leukemia (AML)Untreated AMLAML Arising From Myelodysplastic Syndrome (MDS)AML Arising From Antecedent Hematologic Disorder (AHD)AML Arising After Exposure to Genotoxic Injury

Interventions

DRUG

AG-120

DRUG

AG-221

DRUG

cytarabine

DRUG

daunorubicin

DRUG

idarubicin

DRUG

mitoxantrone

DRUG

etoposide

Trial Locations (17)

10021

Memorial Sloan Kettering Cancer Center, New York

21231

Johns Hopkins University, Baltimore

37232

Vanderbilt University Medical Center, Nashville

43210

Ohio State University, Columbus

60637

University of Chicago, Chicago

75390

University of Texas Southwestern Medical Center, Dallas

77030

MD Anderson Cancer Center, Houston

80045

University of Colorado, Aurora

89081

Universitatsklinikum Ulm, Ulm

90024

UCLA Medical Center, Los Angeles

91010

City of Hope, Duarte

02114

Dana Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston

07601

Hackensack University Medical Center, Hackensack

29425-0001

Medical University of South Carolina - PPDS, Charleston

1081 HV

VU Medisch Centrum, Amsterdam

3075 EA

Erasmus MC, Rotterdam